KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EPS (Weighted Average and Diluted) (2016 - 2025)

Boston Scientific's EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $0.45 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 18.42% year-over-year to $0.45; the TTM value through Dec 2025 reached $1.94, up 55.2%, while the annual FY2025 figure was $1.94, 55.2% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.45 at Boston Scientific, down from $0.51 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.53 in Q2 2025 and bottomed at $0.06 in Q4 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.26 (2021), against an average of $0.27.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 2200.0% in 2021 before it crashed 69.57% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.06 in 2021, then soared by 50.0% to $0.09 in 2022, then surged by 277.78% to $0.34 in 2023, then increased by 11.76% to $0.38 in 2024, then grew by 18.42% to $0.45 in 2025.
  • Per Business Quant, the three most recent readings for BSX's EPS (Weighted Average and Diluted) are $0.45 (Q4 2025), $0.51 (Q3 2025), and $0.53 (Q2 2025).